Synaptogenix (NASDAQ:TAOX) Trading Down 10.4% – Time to Sell?

Synaptogenix, Inc. (NASDAQ:TAOX) dropped 10.4% during mid-day trading on Friday . The company traded as low as $3.29 and last traded at $3.29. Approximately 130,224 shares traded hands during mid-day trading, an increase of 51% from the average session volume of 86,513 shares. The stock had previously closed at $3.67.

Analyst Ratings Changes

Several analysts have recently commented on TAOX shares. Wall Street Zen upgraded shares of Synaptogenix from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Synaptogenix in a report on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has a consensus rating of “Sell”.

Synaptogenix Price Performance

The company has a market capitalization of $24.58 million, a PE ratio of -0.25 and a beta of 1.42. The business has a 50-day moving average of $3.88 and a 200 day moving average of $4.58.

Synaptogenix (NASDAQ:TAOX) last posted its earnings results on Wednesday, May 13th. The company reported $0.43 EPS for the quarter. The firm had revenue of $5.96 million for the quarter.

About Synaptogenix

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University.